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Abstract: The worldwide limited availability of suitable corneal donor tissue has led to the 
development of alternatives, including keratoprostheses (Kpros) and tissue engineered (TE) 
constructs. Despite advances in bioscaffold design, there is yet to be a corneal equivalent that 
effectively mimics both the native tissue ultrastructure and biomechanical properties. 
Human decellularized corneas (DCs) could offer a safe, sustainable source of corneal 
tissue, increasing the donor pool and potentially reducing the risk of immune rejection after 
corneal graft surgery. Appropriate, human-specific, decellularization techniques and  
high-resolution, non-destructive analysis systems are required to ensure reproducible 
outputs can be achieved. If robust treatment and characterization processes can be 
developed, DCs could offer a supplement to the donor corneal pool, alongside superior cell 
culture systems for pharmacology, toxicology and drug discovery studies.  
Keywords: decellularization; extracellular matrix; cornea; tissue engineering 
 
  
OPEN ACCESS 
J. Funct. Biomater. 2013, 4 115 
 
1. Introduction 
Corneal blindness encompasses a complex profile of clinical indications, all presenting with a loss 
of functional vision that affects millions of people worldwide [1–4]. Blindness such as this can have 
numerous causes and can range in severity, but in most cases corneal graft surgery is the most viable 
treatment option [5]. The use of cadaveric donor corneal grafts (allografts) for transplantation is 
routine in current clinical practice. The introduction of tissue quality controls and donor screening has 
improved success rates of transplantation operations, making corneal transplantation the most 
successful human tissue transplantation procedure [3,6,7]. Despite this, 1 in 6 full thickness corneal 
transplants experience some degree of rejection [8].  
Arguably, the biggest current limitation to corneal transplantation is the supply of high quality 
donor tissue [9]. This shortfall differs drastically between territories, with westernized nations 
generally well provided for [10,11], and demand in Africa and Asia considerably outstripping  
supply [11,12]. The increasing worldwide trend for refractive surgery procedures [10,11], cultural and 
religious concerns related to the use of cadaver corneas [11], and the short shelf-life of suitable  
corneas [13], all add to tissue shortages, resulting in over 10 million untreated patients globally [14].  
The current and projected donor shortages are a driver for many to develop feasible long-term 
alternatives to cadaveric corneal donor tissue. Ideally, an alternative should be equivalent, preferably 
superior to cadaveric donor tissue. In order to achieve this, many demands must be met. A corneal 
tissue equivalent needs to be biocompatible; have the spatial architecture of the native tissue so that it 
is optically transparent; be strong to withstand manipulation in culture, potential suturing, irrigation 
and handling during surgery; have a flexible structure so that it can take the shape of the eye and lay 
flat on the surface and also have the ability for oxygen and nutrient transfer through the structure. The 
manufacturing process needs to be easily reproduced with consistent quality, preferably at high speed 
and low cost. 
Alternatives currently in clinical or pre-clinical development can be categorized into the following 
areas: keratoprostheses (KPros), xenografts, tissue engineered (TE) constructs and more recently 
decellularized corneas (DCs). A KPro is an acellular synthetic implant that is intended to be biologically, 
mechanically and functionally attached to the eye [15], permit visible light transmission, whilst 
protecting the retina from ultraviolet (UV) damage [16]. Current examples of KPros that have undergone 
clinical trials include AlphaCor™ [17–19] and the Boston Type 1 [20]. Xenografts occur when 
tissue(s) from one species are transplanted into a different species. Many attempts have been made to 
transplant animal corneas into humans, including the use of cows, dogs, fish, gibbons, pigs, sheep and 
rabbits [11]. Porcine corneas are most commonly used as they have a similar physiology and refractive 
properties compared to human corneas and are relatively easy to obtain [21]. However, xenografts for 
corneal replacement do not have to be of corneal origin. For example, van Essen et al. (2013) [22] 
recently reported the use of fish scales harvested from the Tilapia fish as an alternative tissue source, 
as the organized collagen fiber arrangement is reminiscent of the human corneal stroma. Tissue 
engineering (TE) can be described as ―the production of biological or semi-synthetic living tissue for 
use as replacement tissues for damaged or diseased tissues‖ [23]. Often, it is the generation of a 
synthetic tissue by seeding isolated, specific cells into or onto a template (often referred to as a 
scaffold) and culturing it in a dynamic environment with the aim to eventually form a tissue which 
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mimics the morphological, physiological and biochemical properties of the natural tissue as closely as 
possible. However, the resulting construct does not necessarily have to be cellularized. TE corneal 
replacements can be manufactured using natural materials such as collagen, fibrin, gelatin or alginate, 
or from synthetic polymers such as poly(ethylene glycol) (PEG), poly vinyl alcohol (PVA) or poly 
(acrylic acid) (PAA) or a combination of both natural and synthetic materials [24].  
The advantages and disadvantages of Kpros, xenografts and TE corneas have been summarized  
in Table 1. 
Table 1. Alternative techniques to corneal allografting, advantages and disadvantages. 
Corneal replacement Advantages Disadvantages 
Keratoprostheses: (KPros) 
an acellular artificial implant. 
Currently the only synthetic corneal 
replacements with market approval [14]. An 
alternative treatment for patients considered 
untreatable by conventional corneal 
allografting [25,26]. KPro implantation 
procedure is no more invasive or complex 
than routine corneal transplantation [27]. 
KPro procedure is reversible [27]. Clinical 
data is being accumulated. Scheduling 
independent of human donor availability.  
Success is dependent upon patient maintenance of the 
device [16]. Many KPro materials are  
non-cell adhesive and require modification to allow for 
cell adhesion and migration [28]. Several 
complications have been seen including: wound leaks 
[3,20]; inflammation and infection due to protein 
adhesion [29,30]; increased glaucoma [27,31,32]; 
extrusion or protrusion of the implant [3,25,29]; tissue 
melting [3,32]. Some common eye drugs are also 
harmful to certain types of KPros [19]. Limited  
long-term success [3]. Limited clinical use [27]. 
Xenograft: 
A cellular or acellular tissue 
graft derived from another 
species [33]. 
A virtually unlimited organ, tissue and cell 
source. Scheduling independent of human 
donor availability [34]. Porcine corneas are 
most commonly used and have a similar 
physiology and refractive properties 
compared to human corneas and are 
relatively easy to obtain in large numbers 
[21] thus, are commercially advantageous 
[9,11]. Clinical trials using porcine 
xenografts currently underway.  
Commonly used porcine corneas may be unacceptable 
based on religious beliefs (Islam, Judaism, Jainism) 
[11]. All xenografts eventually fail due to immune 
response. Xenografts are rejected more quickly than 
allograft tissues when similar tissues and 
circumstances are compared [35]. Risk of cross-
species disease transmission. 
Poor public perception. 
Tissue Engineered (TE) 
constructs: a manufactured 
biological or semi-synthetic 
constructs that can be cellular 
or acellular. 
Compelling advances in the development of 
synthetic corneal replacements and culture of 
human corneal cells onto and within 
supporting substrates. It has already been 
shown that the three main corneal layers can 
be recreated in vitro using collagen-based 
scaffolds and immortalized cell  
lines [36]. Success in Phase 1 clinical trials 
have been reported for acellular corneal 
matrices [14]. 
Gross measurable results of TE corneas are  
poor [9,16,37]. Lack of tensile strength to permit 
surgical manipulation and attachment of the corneal 
equivalent. Failure to mimic native surface  
curvature [38]. Lack of the native stromal  
architecture [39]. Biomechanical and optical properties 
of the cornea models are often compromised [40]. 
Presently, there is no cellularized TE corneal 
equivalent in routine clinical use. No standardized cell  
sources available.  
2. Human Decellularized Corneas—A more Promising Alternative? 
The drawbacks of allografts, KPros, xenografts and TE corneal constructs have led to the exploration 
of human DCs as an alternative. A DC is one in which all the cells and cellular components have been 
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completely removed, through chemical, biological or physical methods, leaving a biological scaffold 
of native extracellular matrix (ECM) proteins. The resulting ECM-derived scaffolds are becoming 
progressively popular [41,42] as a possible scaffolds for in vitro corneal modeling [43,44] and as an 
alternative tissue source for corneal transplantation. DC matrices are well suited, but not limited to, 
deep anterior lamellar keratoplasty (DALK) procedures [45]. They have also been investigated as a 
carrier for in vitro expanded human endothelial cells for use in Descemet’s stripping endothelial 
keratoplasty (DSEK) [46,47].  
DCs differ from TE corneas or KPros because the native structure is already present, as nature 
intended; i.e., the DC has not been manufactured, synthesized or produced in any manner, as in the 
case of TE constructs or KPros. An acellular corneal xenograft can technically be classed as a DC, 
however, in this review they are referred to as separate entities, as corneal xenografts are not always 
acellular or corneal in origin. In addition, xenograft corneal DCs may have subtle interspecies 
differences regarding the tissue anatomy and physiology.  
DCs are potentially advantageous in comparison to TE corneal equivalents and KPros because the 
matrix has the ultrastructure of the native tissue. In addition, many of the inherent biological signals 
may remain within the matrix [48], which is likely to be important for the maintenance of specific 
cellular functions and phenotype [41,48]. Such native signals are extremely difficult to synthetically 
manufacture in TE corneal constructs and are completely lacking in KPros. The three-dimensional 
(3D) architecture, surface topography and ECM composition all contribute to cell proliferation, 
differentiation and remodeling processes. The cytokines and growth factors (GFs) present in an intact 
corneal ECM are potentially powerful modulators of cell behavior [48]. The exogenous addition of 
growth factors and their effects on cellular and extracellular behavior have been extensively 
investigated [49–53]. However, the interplay between factors such as dose, binding sites, delivery, 
sustainability and the ability to control GF activation and deactivation have all made the exogenous 
use of GFs as a therapeutic agent extremely difficult [48]. These problems can potentially be evaded 
by the use of DC ECM with intact GFs, proteins and cytokines, providing a scaffold that has all the 
attendant signals (and inhibitors) in their native, relative amounts [48]. However, it is highly probable 
that these may be denatured and/or lost during the decellularization process. 
It has been estimated that 100,000 corneal transplants are performed annually worldwide [13]. 
Between 2011 and 2012 in the UK alone, 5871 corneas were reported to be donated to the UK 
transplant registry [54], of these 3520 were grafted. The remaining corneas were deemed to be 
unsuitable for transplantation for a variety of reasons: 11% due to medical contraindications; 14% due 
to insufficient tissue quality; 5% had fungal/bacterial infections; 4% were out-of date and the 
remaining were incorrectly stored in ethanol. This data for the UK alone represents a possible avenue 
to source human corneal tissue for decellularization. Recently, the UK Eye Retrieval Scheme (ERS) 
have issued an upper age limit of 89 years for corneal donation with the aim of improving the quality 
of donated corneas. This results in a reduction of approximately 7% of corneas into the donor pool, 
which could also potentially be utilized for decellularization techniques [54]. These numbers represent 
a potential tissue supply that could be used to produce a standardized bank of human DCs. To realize 
this, first and foremost, requires the development of appropriate decellularization protocols. Several 
have been explored in the literature in relation to the cornea. 
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3. Methods of Decellularization 
The principal aim of any decellularization technique is the complete removal of cellular material 
and antigen molecules whilst retaining the structural and functional properties of the ECM [41,55]. 
The removal of cellular materials and associated debris should diminish any potential host rejection or 
immunological response. The purpose of corneal decellularization protocols is to produce a functional, 
biocompatible tissue that is readily transplantable. Maintenance of the tissue architecture, protein and 
glycosaminoglycan (GAG) content is particularly important to corneal tissue as the corneal stroma has 
the most organized ECM in the body [56]. It is the uniform collagen fibril alignment of the corneal 
stroma that is vital to tissue transparency [57,58]. The collagen fibers are a heterogeneous mix of 
collagen type I (80%) and collagen type V (20%) fibers; collagen type VI is also present, but forms a 
separate filamentous network that may help negotiate the interactions between the collagen type I and 
V fibers, and the proteoglycans [59]. The collagen fibrils themselves are weak light scatterers as their 
diameters (25–35 nm) are less than the wavelength of light with a refractive index close to that of the 
corneal ground substances [59,60]. They are assembled parallel to each other in 200–250 nm thick 
orthogonally arranged lamellae. The maintenance of this unique structure is a critical design 
consideration when planning corneal decellularization protocols. It is important to note that the 
protocols required to completely remove all cellular material will inevitably cause the most tissue 
disruption. Likewise, decellularization techniques, which maintain the ECM ultrastructure, are very 
likely to leave cellular artifacts and residual antigen molecules. Thus, a balance between the ECM 
ultrastructural disruption and sufficient removal of antigenic and immunogenic material is required. 
Existing decellularization protocols vary hugely depending upon the tissue, organ and species of tissue 
being decellularized [42]. There is currently no reliable or standardized protocol for the decellularization 
of human corneas. Tissue origin (species) and the decellularization and sterilization procedures vary 
widely amongst studies. It should be noted that the method of preparation of DCs can dramatically alter 
the cellular and host remodeling response [48]. In addition, published decellularization protocols often lack 
full characterization of the decellularized tissue, resulting in misleading results.  
Generally, decellularization includes the lysis or removal of the cellular membrane followed by an 
enzymatic treatment that separates cellular components from the ECM. Cytoplasmic, nuclear 
components and cell debris are then removed via the use of detergents, with mechanical agitation to 
increase effectiveness [42]. Following the removal of the cellular components it needs to be ensured that 
all residual chemicals are removed [42]. It may be that the optimal decellularization process requires 
making use of a number of different chemical, biological, and physical methods to achieve a fully 
decellularized tissue with minimal damage to the native ultrastructure. Thus far, several techniques have 
been used on the cornea including biological, chemical, and physical methods (Table 2). Most of these 
efforts have involved the use of animal-derived tissue, the most common utilizing bovine and porcine 
corneas [9,61–69]. However, feline [70,71] and human tissue [46,72] have been utilized in some 
instances. An outline of these techniques and their applicability to the human cornea are presented. 
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Table 2. Decellularization methods previously used for the cornea. 
Method/Technique Mechanism of action Advantages/Disadvantages References 
Biological 
Enzymatic Agents 
Trypsin 
Hydrolyzes protein and disrupts  
protein-protein interactions. 
Disruptive to collagen structure. 
Not suited to corneal tissue. 
[6,64] 
Dispase 
Cleaves peptides associated with 
basement membrane proteins. 
Can aid decellularization process by 
initially removing epithelium and 
endothelium. May cause damage to 
basement membrane. 
[6,62,64] 
Phospholiphases A2 
(PLA2) 
Hydrolyzes phospholipid components  
of cells. 
No interaction with collagen or 
proteoglycans. 
[68,71,73,74] 
Nucleases (RNase and 
DNase) 
Cleaves nucleic acids and aid in  
their removal. 
Effective at removal of DNA and 
residual cellular components that have a 
tendency to adhere to ECM proteins. 
Incomplete removal of the enzymes may 
impede recellularization and successful 
transplantation. 
[6,44,64] 
Sera 
Serum nucleases degrade DNA  
and RNA. 
Effectively removes cells while 
maintaining tissue transparency. 
Use of non-human sera carries risk of 
cross-species transmission of pathogens. 
[12] 
Non-enzymatic Agents 
EDTA 
Dissociates cells by separating  
metal ions. 
Ineffective at cell removal when used 
unaccompanied. 
[47,69,75] 
Chemical 
Alcohols 
Ethanol 
Dehydrates and lyses cells. Removes 
lipids from tissues. 
Can cause damage to ultrastructure of 
tissue. 
[76] 
Glycerol 
Dehydrates and lyses cells. Removes 
lipids from tissues 
Antimicrobial, antifungal, and  
antiviral properties. 
Cryoprotectant for long-term tissue 
storage. Can maintain or restore corneal 
transparency. 
[45,47,64,69,77,7
8] 
Acids and Alkalis 
Peracetic acid 
Solubilizes cytoplasmic components of 
cells. Removes nucleic acids via 
hydrolytic degradation. 
Acts to simultaneously sterilize tissue. 
Poor results in DCs. Can disrupt ECM. 
[76] 
Ammonium hydroxide 
Hydrolytic degradation of 
biomolecules. 
Can eliminate GFs and reduce 
mechanical properties. 
[46,78] 
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Table 2. Cont. 
Method/Technique Mechanism of action Advantages/Disadvantages References 
Ionic Detergents 
Sodium dodecyl sulfate 
(SDS) 
Solubilizes cell membranes and  
dissociate DNA from protein. Disrupts  
protein-protein interactions. 
Complete removal of cells can be 
achieved. Can be highly detrimental to 
ECM structure including disorganization 
of collagen fibrils and loss of GAGs. 
Loss of tissue transparency. 
[47,61,64,65,69,7
2,75,76,79] 
Sodium deoxycholate 
(SD) 
Solubilizes cell membranes and  
dissociates DNA from protein. Disrupts  
protein-protein interactions. 
Less effective at removal of cells but can 
be effective when used with other 
agents. 
[68,79] 
Non-ionic Detergents 
Triton X-100 
Breaks up lipid-lipid and  
lipid-protein interactions. 
Mild and non-denaturing. 
Less effective than ionic detergent 
treatments. 
Can cause damage to ECM structure. 
[6,44,46,78,80] 
Zwitterionic Detergents 
3-[(3-
Cholamidopropyl)dimeth
ylammonio]-1-
propanesulfonate 
(CHAPS) 
Has properties of non-ionic and 
ionic detergents. 
Poor cellular removal. 
Very disruptive to stromal architecture. 
[79] 
Hypo- and Hypertonic Solutions 
Sodium Chloride (NaCl) Detaches DNA from proteins. 
Remains optically clear. 
Ability to maintain stromal architecture and 
retain GAG content. 
Mixed reports on success of cell removal. 
[62,64] 
Tris-HCL Lyses cells by osmotic shock. 
Reduces time required in harsh 
decellularizing agents. 
[6,44,69,75] 
Physical 
Freeze-thawing 
Ice crystal formation causes cell 
lysis. 
Requires subsequent treatment to remove 
cellular content. 
Causes pore formation. 
Disruptions to ECM architecture. 
[64,74,79] 
Hydrostatic Pressure 
Increase in pressure results in cell 
lysis. 
Effectively decellularizes whilst maintaining 
collagen fibril structure. 
Kills bacteria and viruses. 
Expensive. 
[63,66] 
3.1. Biological Decellularization Techniques 
3.1.1. Enzymatic Agents 
Enzymatic decellularization protocols are advantageous in that they provide high specificity for the 
removal of cellular and detrimental ECM elements [41]. However, residual enzymes in decellularized 
tissues are particularly problematic as they may impair recellularization whilst stimulating immune 
responses such as severe apoptosis and inflammation, which result in early rejection of DCs [64].  
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Dispase, trypsin and collagenase are commonly used enzymatic treatments. Epithelia and endothelia 
have been removed following treatment with Dispase II [6,62] before being fully decellularized using a 
subsequent method. Dispase cleaves peptides associated with specific basement membrane proteins such 
as collagen IV and fibronectin, but it can also cause damage to the basement membrane if used for 
prolonged periods [81]. Trypsin is frequently used as an initial or additional treatment to improve the 
infiltration of other decellularization agents. However, it should be used with caution, as it is disruptive 
to collagen, despite showing better preservation of proteoglycans [82]. To this end, it may not be well 
suited to corneal decellularization, where preservation of collagen structure is crucial for the maintenance 
of the tissue’s optical clarity. 
Phospholipase A2 (PLA2) is an esterase that hydrolyses phospholipid components of cells but does not 
react with collagens or proteoglycans [68]. When combined with bicarbonate salt solutions it has been 
shown to effectively remove cells in the cornea while keeping the collagen structure intact [68,71]. 
However, a significant reduction in GAG content has been noted [68]. The addition of 0.5% sodium 
deoxycholate (SD) allowed for the incubation time to be reduced from 24 hours to 8 hours by increasing 
the hydrolytic activity of PLA2, thereby substantially reducing loss of hydrosoluble GAGs [68]. 
Nucleases such as RNase and DNase, are frequently used following enzymatic protocols, to cleave 
nucleic acids and aid in their removal [44,64,72]. Porcine corneas treated with DNase and RNase 
resulted in complete removal of cells but the tissue became opaque due to severe distortion of the 
collagen structure [64]. Transplantation into a rabbit model culminated in immediate corneal melt. 
From this, it is clear that complete removal of the enzyme is necessary for successful recellularization 
and clinical use. 
Sera, such as fetal bovine serum (FBS), contain nucleases that can degrade both DNA and RNA [83]. 
As such, it supports the removal of nucleic acid from tissue, but fails to remove immunogenic  
elements [41]. Various concentrations of FBS have been tested in modified detergent-based 
decellularization protocols to remove residual DNA fragments [83]. Xenogeneic serum has the 
disadvantage of introducing immunogenic elements into the ECM which can cause adverse immune 
responses following recellularization or tissue transplantation into the host [41]. The use of FBS and 
other sera for complete DNA/RNA removal may limit the time needed in harsh detergents. Moreover, 
human serum has also been used alone as the decellularizing agent to produce porcine DC, after first 
mechanically removing the epithelium [12]. 
3.1.2. Non-Enzymatic Agents 
Non-enzymatic treatments include the use of chelating agents and serine protease inhibitors. 
Chelating agents such as ethylenediaminetetraacetic acid (EDTA) aid cell dissociation via the separation 
of metal ions [84]. However, these same mechanisms can lead to the disruption of protein-protein 
interactions [41,85]. Chelating agents are often used in combination with enzymes and detergents, as 
unaccompanied they are insufficient for superficial cell removal [41,86–88]. EDTA has been used 
together with sodium dodecyl sulfate (SDS), an ionic detergent [47], to decellularize corneal  
tissue [47,69,75].  
Serine protease inhibitors such as aprotinin, phenylmethylsulfonyl fluoride, and leupeptin, can 
prevent some of the detrimental effects to the ECM caused by intracellular proteases released by lysing 
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cells. Protease inhibitors are often used as an accompaniment to harsh detergents and decellularizing 
agents. Commonly used for the cornea is aprotinin [47,61,69,79], an inhibitor of trypsin and related 
proteolytic enzymes. In these studies, authors have reported minimal damage to the ECM despite the 
use of harsh decellularizing agents [61,69].  
3.2. Chemical 
3.2.1. Acid and Alkali Treatment 
Acid and alkali treatments are effective at solubilizing the cytoplasmic components of cells and the 
removal of nucleic acids [42] by causing or catalyzing hydrolytic degradation of biomolecules [41]. 
However, such solutions may also remove important molecules such as GAGs from collagenous 
tissues. For example, acid use has been associated with the damage and removal of collagen from 
tissues, which reduced ECM strength, but retained sulfated GAGs [41,89]. Likewise, alkali treatments 
such as ammonium hydroxide have been associated with the removal of GFs and a reduction in ECM 
mechanical properties [90].  
Peracetic acid has been investigated as a decellularizing agent [76,91,92]. Limited success has been 
reported with corneal tissue when used alongside ethanol, however, the authors considered further 
optimization was necessary [76]. Advantageous for its ability to disinfect, its use has been proposed 
for preclinical sterilization of acellular scaffolds and reported superior to other clinically accepted 
methods [93]. In addition, peracetic acid has been reported to retain GAG content and preserve the 
structure and function of important GFs [42]. 
Ammonium hydroxide is an alkali treatment that has been used in conjunction with the detergent 
Triton X-100 to decellularize human corneas [46]. The treatment was reported to result in a complete 
DC with little apparent effect on the collagen architecture and basement membrane proteins [46]. 
3.2.2. Alcohols 
Alcohols aid decellularization by dehydrating and lysing cells [41,94]. Alcohols such as ethanol and 
isopropanol are commonly used to remove lipids from tissue. Care should be taken when using them 
as a decellularizing agent, as they can also act as a tissue fixative [95,96], precipitate proteins [95], 
damage the ECM ultrastucture [41], and dehydrate the tissues causing tissue opacity [55]. A remedy to 
this is soaking the tissue in distilled water, which can reverse tissue dehydration [91]. Previously, 
ethanol treated corneas have resulted in complete tissue decellularization whilst maintaining the 
overall tissue structure [76]. Interestingly, corneal stromal cells cultured on ethanol treated DCs were 
reported to proliferate slower and produce more new ECM components, in comparison to those 
cultured on DCs treated with a detergent method [76]. Moreover, the latter showed a decrease in 
collagen content over the same culture period. 
Glycerine dehydration has been used since the 1960’s for prolonged storage of donor corneas for 
later transplantation [97–99]. More recently, in vivo confocal microscopy techniques have shown that 
antigen presenting cells and stromal cells were, in fact, absent in glycerine-cryopreserved allografts 
(GCA) used in transplantation procedures into human recipients [45]. These DCs showed promising 
results when transplanted into patients with high rejection risk due to infection and inflammation [71]. 
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In one such clinical study, no rejection was seen with the GCA, while 10% of eyes that received fresh 
corneal allografts (FCA) reported episodes of stromal rejection [71]. Another clinical study reported 
similar findings with no rejection cases in the GCA group and one case of stromal rejection in the FCA 
group [45]. This suggests that glycerol cryopreservation may be a promising technique for producing 
DCs for use in corneal grafting procedures, with apparent clinical efficacy. Glycerol has also been 
used as a post-treatment to restore corneal transparency [47,69] and as a preservation technique for 
DCs. Detergent-treated bovine DCs snap frozen in 100% glycerol and stored for several days were 
transparent upon rehydration [78]. Poly(ethylene glycol), an amphiphilic copolymer that damages cells 
membranes, has been also used as a decellularizing agent [72]; although, it was shown to be ineffective 
at removal of cells and cellular debris [72]. 
3.2.3. Detergents 
By far the most commonly employed method of decellularization is the use of detergents including, 
but not restricted to, ionic, non-ionic and zwitterionic detergents. These effectively solubilize the cell 
membrane and dissociate DNA from proteins [100,101], but at the cost of disrupting and removing 
valuable ECM proteins [61,90,102]. The removal and disruption of ECM components increases with 
exposure time, which should therefore be minimized [61]. 
Non-ionic detergents are considered to be milder than ionic treatments as they target lipid-lipid and 
lipid-protein interactions, as opposed to protein-protein interactions [55]. Triton X-100 has frequently 
been used in corneal decellularization protocols [6,44,46,78–80]. However, its use has been criticized 
for the apparent failure to effectively reduce and remove cellular material from tissue [61]. To 
decellularize the cornea it has been used alone [79,80] and in combination with other agents including 
hydroxylamine [46,78]; Dispase II, for removal the corneal epithelium [44] and nucleases, to aid in the 
complete removal of cellular debris [44]. These confounding factors have made it difficult to assess 
detergent efficiency and the effects on the ECM, in the latter cases. However, in all cases successful 
decellularization was reported.  
A strong ionic detergent also commonly used in decellularization protocols for the cornea is  
SDS [47,61,64,65,72,76,79], as it is effective at solubilizing cellular membranes and complete removal 
of cells has been reported [61,72]. Although more effective than Triton X-100 at removal of cellular 
material, including complete removal of cell residues, disruption of the ECM has occurred [72] even at 
concentrations as low as 0.1% (v/v) [62]. Contradictory reports have shown that when used at low 
concentrations (between 0.5 and 1% (w/v)), corneal architecture, GAG and collagen content were 
unaffected [61]. This may be due to inter-species variation or dependent upon the addition of protease 
inhibitors that can protect the ECM structure and components. Nonetheless, a need for standardized 
procedures and characterization techniques is highlighted. A reduction in corneal transparency is also 
associated with the use of SDS [61,62,79]. As previously mentioned, tissue transparency can be 
restored via the use of glycerol [65]. The decellularization process can cause swelling of the tissue, and 
the dehydrating effects of glycerol return it to a state of deturgescence. Moreover, it has been reported 
that in a rabbit model, initially opaque DCs recovered their original transparency, 8 weeks  
post-transplantation, without the use of glycerol treatment [61]. Sodium deoxycholate (SD), another 
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ionic detergent, has also been investigated [71], but appears to be less effective than SDS in the 
removal of cellular material whilst equally detrimental to the ECM [79].  
Zwitterionic detergents such as 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS) have been criticized as they reportedly leave residual nuclei and cell fragments in the 
stromal tissue [79]. When used for corneal decellularization, poor cellular removal, as well as damage 
to ECM proteins has been reported [79]. 
3.2.4. Hyper- and Hypo-tonic Solutions 
Hypotonic solutions, such as tris buffer, can lyse cells via osmotic shock, while hypertonic saline 
can detach DNA from proteins [100]. Decellularization by immersion in alternating hypo- and 
hypertonic solutions can increase the osmostic effect [41,100,103]. Conveniently, this also supports the 
removal of cell debris following lysis [41]. The use of hypertonic sodium chloride (NaCl) solution has 
been investigated for DCs [62,64] and is known to cause minimal damage to stromal architecture and 
retain many extracellular GFs and proteoglycans. Hence, DCs are reported to be optically clear 
following treatment [62,64]. However, these treatments are generally less effective at removing cells 
than, for example, detergent-based methods and incomplete decellularization has been observed in 
most cases. As a result, protocols may often be modified to include the use of nucleases such as DNase 
and RNase [6,72].  
Tissues can be incubated in hypotonic tris-HCl buffers, as a pre-treatment at 4 °C, to initially lyse 
cells before further treatment with enzymes and/or detergents [6,44,69,75]. This has the advantage of 
reducing the incubation time needed in the harsher decellularizing solutions.  
3.3. Physical Decellularization Techniques 
Physical decellularization protocols utilize freezing, pressure, sonication and the use of mechanical 
agitation [42,55]. Snap freezing of tissues results in cell lysis via the formation of intracellular ice 
crystals that disrupt cellular membranes (Figure 1A). Xaio et al. (2001) [74] utilized snap freezing 
followed by lyophilization to induce pore formation in DCs. The ice crystals formed during  
pre-freezing are sublimated under vacuum conditions leaving a network of interconnected pores that 
enabled infiltration by cells [103]. 
Freezing and incubating the tissue in nitrogen gas has been used to induce apoptosis, as freezing 
alone can be insufficient [9]. Nitrogen freezing of tissues is a relatively mild treatment when compared 
to enzymatic or detergent treatments [9]. The application of direct pressure to a tissue can cause cell 
lysis whilst causing minimal disruption to the ECM [72]. However, both of the aforementioned 
techniques require additional washing steps to remove the residual lysed cellular material. High 
hydrostatic pressure (Figure 1C) has been reported to successfully decellularize porcine corneas whilst 
maintaining collagen fibril matrix and GAG content [63,66]. The use of high hydrostatic pressure is 
non-cytotoxic, but successfully removes cells whilst destroying bacteria and viruses [55]. One 
drawback is the cost of this expensive technique, which requires specialized equipment capable of 
applying pressures of up to 1 GPa to the corneal tissue [55]. Sonication (Figure 1B) and mechanical 
agitation, in conjunction with chemical and enzymatic treatments, have been used to assist cell lysis 
and removal [42].  
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Mechanical agitation alone can have the effect of lysing cells, but is more often used to facilitate 
chemical exposure [41]. Most published decellularization protocols for the cornea involve some form 
of mechanical agitation for this purpose. The agitation aids the accessibility of the reagents in reaching 
the cellular and nuclear materials [55] and often orbital or rotating shakers are used.  
Figure 1. Schematic representation of physical decellularization protocols. 
 
4. Characterization of Decellularized Corneas 
As discussed, decellularization protocols vary considerably in their efficacy [6], resulting in grafts 
that can elicit a range of in vivo effects [41]. Incomplete removal of cellular material can lead to 
adverse host response, and cytocompatibility issues associated with the DC [104–106]. It is therefore 
important to have sufficient monitoring protocols in practice to discern whether complete 
decellularization, including removal of all cellular debris has occurred, and ECM integrity has been 
maintained following processing. Crapo et al. (2011) [41] proposed a set of minimal criteria to satisfy 
the description of ―decellularized‖: less than 50 ng double stranded DNA (dsDNA) per mg ECM dry 
weight; less than 200 base pair DNA length; and a lack of visible nuclear material when stained with 
4',6-diamidino-2-phenylindole (DAPI) or hemotoxylin. This criteria focuses predominantly on 
characterizing the removal of DNA, as it has been proven that residual DNA is the cause of the 
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majority of adverse host reactions [104,107]. After assessment of the removal of all cellular 
components, characterization can then be performed to assess the retention of the native ECM 
architecture and mechanical properties. Although complete retention of ECM ultrastructure is  
ideal, minimizing the disruption of the ECM architecture is a more realistic objective when optimizing 
decellularization protocols. 
A standard for characterizing decellularized tissue would be of great significance for translating 
decellularized products to clinical applications. For the objective of creating ECM products for TE and 
regenerative medicine purposes, demonstrating successful characterization validates a decellularization 
technique as effective, consistent, reproducible and suitable for manufacturing purposes.  
4.1. Assessment of Removal of Cellular Materials and Retention of ECM Architecture 
4.1.1. Removal of Cellular Materials 
The most popular method of assessing the removal of cellular material is performance of a DNA 
stain, followed by imaging. Amongst possible stains, hemotoxylin is used most routinely to assess the 
degree of decellularization, and is usually performed alongside eosin (Figure 2A) to assess basic ECM 
architecture of DCs [9,46,62,63,66–69,72,78,108,109]. Other commonly used nuclear stains include 
fluorescent DAPI [61,62,72] (Figure 2B), Hoechst [9,68] and propidium iodide [72]. Cell apoptosis 
that occurs during the decellularization process, can be assessed by assays such as the TUNEL assay, 
which detects levels of DNA fragmentation, by fluorescently labeling the terminal end of nucleic  
acids [9,67]. Although, DNA staining and imaging is the standard for assessing decellularization, and 
is used throughout the body of literature, it is relatively insensitive and offers no quantitative information.  
For quantitative information regarding residual DNA, DNA can be extracted from the DCs and 
spectrophotomic assays such as Pico green or Hoechst used [83,90]. Remaining DNA fragment size 
can also be assessed by gel electrophoresis, to determine how successful the decellularization process 
has been in breaking down the cellular components. The disadvantage of performing these assays and 
staining protocols to assess residual DNA, is that destruction of the sample is required.  
Figure 2. (A) Native corneal structure and cellular nuclear staining using hemotoxylin and 
eosin staining; and (B) DAPI. 
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4.1.2. Biological Assessment of ECM Architecture 
Preservation of the native tissue architecture and ECM composition during tissue decellularization 
is the ultimate aim of decellularization protocols [41]. This is true of all decellularized tissues, but is of 
particular interest to DCs, as the corneal stroma has the most organized ECM in the body and it is this 
structure that is responsible for corneal transparency [56]. Basic histology can be used to compare the 
architecture of DCs with the native cornea. Stains such as eosin and van Gieson’s have shown 
immediate changes in collagen structure [61,79]. However, basic histology does not always offer 
enough specificity, and in such cases, immunohistochemistry is a useful tool as it is capable of 
detecting corneal specific ECM proteins. Corneal specific proteins commonly utilized include 
collagens I, II, III, IV and V, keratin, fibronectin and laminin, present in the basement  
membrane [46,61,72]. If a fully intact DC is the final goal, then determining the presence and integrity 
of the Bowman’s layer and Descemet’s membrane is important, and the identification of specific 
proteins, rather than a general eosin stain, will give more information. To identify other components of 
the DC, stains such as Alcian blue have been used as a way of assessing whether the GAG content 
within the corneal stroma has been retained [62,90].  
4.1.3. Toxicity and Immunogenicity of Decellularized Corneas 
It is important to consider how the host may respond to a DC, specifically the immune response and 
particularly when employing xenogeneic decellularized tissues. An important factor in the rejection of 
xenogeneic tissue is the α-Gal (Galα1-3Galβ1-4GlcNAc-R) epitope [110–112]. Ideally, traces of this 
epitope should be removed throughout the decellularization process, evidence for which has been 
provided by immunohistochemistry or enzyme-linked immunosorbence assays (ELISA) [62,113]. The 
presence of the α-Gal epitope is one potential driver to move away from the use of xenogeneic grafts. 
The use of allogeneic human tissue may also produce an immune response through the presence of 
major histocompatibility complex (MHC) antigens displayed on donor cells; specifically in humans 
referred to as human leukocyte antigens (HLA). There are two classes of HLA antigens, class I, which 
are expressed by almost all nucleated cells of the body including cells of the cornea; and class II, 
which are only expressed by antigen-presenting cells such as macrophages, B cells and dendritic cells, 
not normally present in the cornea. HLA class I antigens present peptides from inside a cell. The  
T-cells and natural killer (NK) cells of a host recognize foreign HLA class I antigens, such as those 
from allogeneic implanted cells, and act to destroy the cells, initiating the immune response and 
inflammation, resulting in graft rejection [114,115]. However, DCs should not cause an HLA-mediated 
immune response because in theory, all cells and cellular debris, including HLA antigens, have been 
removed during the decellularization process.  
Performing transplantations of DCs in vivo into animal models provides crude information on the 
relative immunogenicity of the implant [6,9,63]. In vivo models, typically rabbit, are used to determine 
the biocompatibility of DCs. This has often been assessed through, recruitment of immune competent 
cells, stromal cell infiltration, epithelialization, transparency and clinical assessments of pathological 
vascularization, and signs of rejection. Often the first and easiest assessment of immunogenicity of 
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decellularized grafts is to implant the DC subcutaneously in vivo [73]. As of yet, there have been no 
studies investigating the systemic immune response caused by implantation of a DC. 
In vivo animal models also give an impression of degradation rate of DCs. DCs are not designed to 
degrade in vivo, as many TE constructs do, but are supposed to be remodeled by cells to integrate into 
the existing tissue. If degradation occurs it is likely to be related to the immunogenicity of the implant. 
Wu et al. (2009) [68] report no degradation and no signs of inflammatory cell infiltration within their 
implanted PLA2 decellularized constructs within 12 months of implantation [68]. However, in 
transplanting an ex-vivo recellularized DCs, Zhang et al. (2007) [6] noted complete degradation within  
12 weeks. Importantly this was associated with an acute infiltration of inflammatory cells. Many 
groups choose to assess cytotoxicity of the DC in vitro by recellularizing the DC with the various cell 
types present in the cornea and performing viability assays, such as MTT [6]. Extract cytotoxicity 
assays are often performed to assess the effect of leachables on cells. An assessment of the safety of 
both extractables and leachables is a requirement of the Food and Drug Administration (FDA) for 
medical device submission [116]. Scaffolds are placed in medium for a defined period of time and the 
effect of the extract on the cytotoxicity of epithelial cells or stromal cells is measured by through the 
use of viability assays [6,12,67]. 
4.2. Imaging of Structural Architecture and Transparency 
Although histological and immunological procedures are useful techniques in biomedical science, 
fixation, labeling and processing techniques can distort cellular expression and tissue architecture [117], 
are often destructive, and only provide information on very small areas of the cornea [118]. Thus,  
the need for non-destructive, high contrast, high resolution and large area imaging techniques is 
apparent [117]. Initially, macroscopic evaluation of the tissue can be performed, as disruption to the 
tissue architecture can result in the occurrence of opacities (Figure 3). However, this crude mechanism 
may not be sufficient to determine micro-scale changes. Furthermore, the transparent nature of corneal 
tissue often makes imaging of corneal internal structures challenging. The following sections discuss 
existing and relevant techniques that have been successful and show potential in monitoring of corneal 
tissues. This may be particularly useful to the decellularization process in assessing the reproducibility 
and the introduction of ―quality control‖ measures to determine what classes as a successful or 
acceptable decellularization protocol.  
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Figure 3. Basic macroscopic evaluation of decellularized corneas can provide a crude 
marker of the success of a decellularization protocol; comparisons of (A) a non-treated 
cornea; versus (B) a cornea treated with strong ionic detergents. It is apparent that the 
detergent-treated cornea is opaque in appearance when compared to the transparent  
non-treated cornea. These opacities are caused by disruption of the tissue architecture due 
to the decellularization process.  
 
4.2.1. Light Microscopy Techniques 
Light microscopy is a relatively simple technique used in the earliest qualitative studies of corneal 
architecture, leading to the first descriptions of the stromal lamellar structure [119]. Transverse tissue 
sections are taken and immunostaining of samples allows for the distributions of different types of 
collagen to be determined [119]. However, the processing and sectioning protocols required to 
visualize the microscopic structures may cause shrinkage or distortion of the tissue samples [119]. 
Additionally, the light reflected and scattered from the structures surrounding the point of interest can 
obscure the image outside of the focal plane, reducing resolving power and image content [120,121]. 
Many techniques are available that modify the light path to improve the resolving power and contrast 
of specimens. Phase contrast microscopy, is one of the simplest techniques and is most useful in 
revealing cellular structures that cannot be seen with standard light microscopy. 
Polarized light microscopy allows quantitative evaluations of collagen organization [119,122]. 
Colored polarized images provide an appreciation of the different orientations of the collagen fibrils in 
normal and pathological corneas. This technique shows promise in discerning structural changes in 
collagen that may have occurred during decellularization.  
Confocal microcopy allows for detailed in vivo observations to be made [119], allowing for lateral 
corneal structures such as the Bowman’s membrane and stroma to be visualized at a resolution of  
1–2 µm [120,123], with a depth of field ranging from 10 to 26 µm [121]. Current confocal systems are 
frequently used in both laboratory and clinical settings [123]. They are utilized for in vivo ophthalmologic 
observations for disease diagnosis [117], degenerative disorders, the effects of refractive surgery 
procedures [120,121] and the effect of contact lens wear [123] as they can detect stromal deposits and 
stromal matrix disruption on living tissues en face [121], without the need for tissue fixation [120], 
invasive preparations or staining protocols [124]. Confocal microscopy can also be used to measure 
corneal transparency by measuring the intensity of backscattered light relative to a healthy cornea. 
This may make a good technique for monitoring DCs compared to healthy, native tissue.  
J. Funct. Biomater. 2013, 4 130 
 
Light microscopy techniques are valuable for initial analysis of surface corneal structure. However, 
information regarding the ECM quality following decellularization can only feasibly be achieved via 
destructive sectioning techniques, so although useful during the development of appropriate 
decellularization techniques, it is not applicable as a screening tool. 
4.2.2. Electron Microscopy 
Electron microscopy is a predominantly qualitative technique used to provide localized information 
on stromal architecture [125]. Compared to light microscopes, electron microscopes have greater 
resolving powers to reveal detailed ultrastructures. 
Transmission electron microscopy (TEM) is capable of revealing ultrastructural details of corneal 
tissue such as fibril diameter, interfibrillar spacing and order of collagen fibrils and is a central 
technique to the understanding of the corneal architecture [57,119,126,127]. Specialized staining 
techniques and metal labeling in conjunction with TEM can reveal the location and distribution of 
binding sites of proteoglycans, that are vital to collagen organization [119]. TEM has previously been 
used to compare species differences in corneal structure [128] and is able to detect and measure the 
thickness of the Bowman’s and Descemet’s membranes [128]. However, it should be noted that the 
fixing protocols and embedding resins required for TEM can alter the collagen fibril diameter and 
intrafibrillar spacing in the corneal tissue [127]. Thus, this may distort or alter the apparent effect that a 
decellularization technique has on a tissue and needs to be considered during analysis.  
Scanning electron microscopy (SEM) is a technique that probes the surface of the specimen 
providing information regarding the surface and topography of the sample. Although the resolving 
power is less than TEM, SEM has been utilized for the evaluation of surface and cellular morphology 
of the anterior surface of the cornea and the determination of 3D lamellar structure [119], in both 
native and regenerated tissues (Figure 4). It can also be used to image larger areas than TEM, as it is 
not reliant upon transmission. Unfortunately, critical point drying techniques used to prepare 
specimens for SEM are associated with a variable amount of specimen shrinkage [129], and harsh 
fixatives may be required. Concerning evaluating decellularized corneal tissue, a combination of both 
SEM and TEM has been successfully used [72]. 
Figure 4. False-colored images of corneal stromal cells (blue) and collagen structure in 
tissue-engineered corneal stromal constructs at relatively (A) high; and (B) low magnification 
imaged using SEM. 
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4.2.3. Second Harmonic Imaging 
In cornea, second harmonic imaging allows for high-spatial resolution and contrast images of 
corneal structures to be achieved that are comparable to light and electron microscope studies [130]. 
The increased resolution allows for deep imaging of corneal depths of up to hundreds of microns to be 
investigated [131,132], displaying the 3D interwoven lamellar structures and the Bowman’s layer [130]. 
This non-invasive technique negates the need for staining, sectioning and additional processing of the 
tissue [130,131]. 
4.2.4. High Frequency Ultrasound 
High frequency ultrasound utilizes acoustic reflections and scattering to create high resolution, 
near-microscope, quantitative imaging of the cornea [133,134]. High frequency ultrasound (50 MHz) 
allows for resolving powers up to 30 µm and improved tissue differentiation, in comparison to 
conventional ultrasonic techniques (8–10 MHz) [134]. The technique has been utilized in many areas 
concerning corneal tissue including: quantitative assessment and analysis of corneal epithelial 
thickness; pathology in response to chronic exposure to various drugs [135]; measurement of the depth 
of incisions following radial keratoctotomy [133]; and most importantly and applicable to screening of 
DCs, stromal thickness measurements and non-invasive assessment and comparison between normal 
and scarred corneal tissue [134,136]. It is an advantageous technique as it is non-destructive [135], 
does not require prior staining or sectioning of the sample, and can provide information on the corneal 
tissue microstructure continually over areas up to 10 mm [134,136]. 
4.2.5. Optical Coherence Tomography 
Optical coherence tomography (OCT) and ultrahigh resolution OCT are both non-invasive imaging 
techniques with micrometer resolution, capable of measuring the cross-sectional structure and 
thickness of materials up to 2 mm [137,138]. Commercially available OCT systems are readily used 
clinically [139]; frequently by ophthalmologists to examine the ocular structure, particularly the retinal 
structure. The resolution of clinically used OCT systems is often equivalent to a low-powered light 
microscope. Confocal and multi-photon techniques are capable of imaging up to 200 μm depth and 
OCT is advantageous in that it does not require fluorescent labeling of samples [139,140] and is 
relatively inexpensive and easily set up, thus is a suitable technique for monitoring DCs. OCT is 
clinically relevant [138] because it allows for fast, sterile, non-destructive, in situ, real-time 
investigations [138,140]. Presently, the resolution of OCT technologies currently used in clinical 
settings is significantly below what is theoretically possible. Ultrahigh resolution OCT has the 
potential to allow for the visualization of intra-corneal architectural morphology with axial resolution 
of 2–3 µm [141], capable of distinguishing the Bowman’s layer and stromal morphology [137], which 
would be a beneficial way of rapidly characterizing corneal tissue following decellularization.  
4.2.6. X-Ray 
David Maurice first pioneered the use of X-rays to examine the collagen fibril arrangement of 
corneal tissue in 1957 [57,142]. Subsequently, X-ray scattering has been extensively used to provide 
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information regarding the typical structural characteristics of the cornea [58,125,143,144] including 
the determination and quantification of the orientation and content of the collagen fibrils throughout 
the entire cornea and limbus [57,118,143]. X-ray scattering has been used to establish whole corneal 
thickness [125] and differences in collagen fibril orientation of normal, keratoconus corneas [143] and 
aging corneas [144]. Theoretically, this technique could be used to determine differences in normal 
corneas and DCs, as the scattering patterns can detect changes in the collagen fibril arrangement [143]. 
Advantageously, X-ray scattering techniques do not require tissue processing that could potentially 
disturb the corneal structure [125].  
4.2.7. Atomic Force Microscopy 
Atomic force microscopy (AFM) has been utilized to investigate the corneal stroma and sclera, and 
is frequently used to confirm TEM observations [119]. However, unlike TEM and SEM, it is capable 
of measuring the ―gap-zones‖ between the corneal collagen fibrils [145]. AFM involves scanning the 
corneal surface with a sharp, finely pointed tip controlled by a piezoelectric motor [119,145]. The 
undulations of the tip are monitored with a laser-diode detector and translated into a 3D topographical 
image [119,145]. AFM is advantageous in that measurements can be taken in both vacuum and  
non-vacuum (air or liquid) environments and it does not require metal-coated conductive samples, as 
are required in electron microscopy [145]. Thus, AFM could be used as a non-destructive screening 
tool for DC matrices. 
4.3. Characterization of Mechanical Properties 
Ultimately, decellularization protocols aim to remove all cellular and nuclear material from the 
tissue. It is important to be able to evaluate the ability of protocols to decellularize the corneal stroma 
without reducing tissue transparency or mechanical strength [9]. Changes to the 3D architecture of the 
tissue due to decellularization protocols will result in alterations to the biomechanical properties of the 
tissue. Thus, the maintenance of tissue strength and elasticity can be used as a measurement of the 
preservation of the ECM. In vivo, the cornea is a viscoelastic [146,147], anisotropic [16], load bearing 
tissue, constantly subjected to forces from intraocular pressure and the movement of the eyelid. Thus, 
it can be assumed that these forces will have an effect and are affected by cell and tissue behavior. For 
example, the biomechanical properties of the cornea have been shown to be an important component 
of the final refractive effect [148]. The aforementioned characterization techniques are primarily 
concerned with structural and biological alterations to the ECM. To date, there are no studies that 
investigate the effect that decellularization has on the viscoelastic properties of the tissue [55]. The 
following section summarizes techniques that have been previously used and adapted, to characterize 
the mechanical properties of the cornea and equivalent tissues. However, many mechanical tests used 
with corneal tissue and equivalents, such as decellularization protocols are not specific to corneas; they 
are existing tests that have been adapted for use on cornea. As such, the various techniques suffer from 
disadvantages and may need further optimization. A summary of some of these methods and their 
advantages and disadvantages can be found in Table 3. 
Measuring mechanical properties of biological constructs is typically very challenging. The 
measurement of mechanical properties under sterile conditions is also highly desirable when 
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monitoring biomechanical processes. Although many mechanical testing techniques are available, it is 
difficult to compare and contrast information, as there are considerable differences in the technological 
means of carrying out the tests. Additionally, the interpretation of results can also contribute to 
discrepancies between data acquired by mechanical testing [149]. 
Table 3. Tests used to monitor the mechanical properties of corneal tissue and tissue 
equivalents; a brief description and common applications; advantages and disadvantages. 
Method/ 
technique 
Description/applications Advantages Disadvantages 
Bulge/inflation 
testing 
Involves inflation of the whole 
tissue/membrane/film through a 
window in the substrate and 
measuring the displacement as a 
function of the applied pressure 
[146,150]. Used to measure 
mechanical strength of thin films, 
membranes and corneal tissue. Can 
determine constitutive relationships 
of corneal tissue [151].  
No gripping problems. Maintains corneal 
integrity [148]. Reliable technique. Enables 
intrinsic properties on a layer-by-layer basis to 
be determined [152]. Can be used to simulate 
intraocular pressure [148]. Can be performed 
under physiological conditions [148,153]. 
Whole tissues can be measured. Previously 
used to characterize DCs [55] and the 
biomechanical stability of xeno-tissues for 
human transplantation [148]. 
Complex procedure [152]. 
Difficulties in controlling 
the applied pressure; i.e., 
leaking or trapping of 
dissolved air. Most inflation 
tests do not account for 
corneal anisotropy [148], 
inhomogeneity or 
viscoelasticity [153]. 
Compression 
testing 
Test materials are compressed 
between two plates and deformed 
under a known load. Used to 
determine the mechanical 
behavior of materials under 
crushing loads [154,155]. 
Regularly used in TE applications [156]. 
Confined and unconfined tests can be 
performed. Gives a comprehensive evaluation 
of a materials load-bearing capacity [155]. 
Does not account for 
corneal curvature. Involves 
flattening of the tissue. 
Difficulties associated with 
applying pressure evenly. 
Destructive [157]. 
Holographic 
interferometry 
Uses laser light to create an 
image. Can be used to compare 
pressure changes in healthy and 
diseased corneas [158]. 
Previously used to determine 
differences between intact, 
incised [159] and laser ablated 
[160] corneas. Measures the elastic 
modulus [161] and extensibility of 
in vivo corneas [162]. 
Very sensitive, precise method. Allows for 
direct comparison of two adjacent areas in a 
single sample. Non-destructive. Allows for 
repeated measures of a sample [158]. 
Rarely used by researchers. 
Limited to use in linear 
elastic materials under 
small deformation [146]. 
Indentation 
testing 
A well-defined indenter is used to 
deform test materials and measure 
their force-displacement curves; 
this can be used to calculate the 
elastic modulus. Traditionally 
used to measure the hardness  
of materials. 
Can be adapted to be non-destructive. Can be 
adapted to test for prolonged culture periods 
under sterile conditions [146,163]. Fast, online 
real-time measurements. Can be performed on a 
nanometric scale. Suspending the materials 
eliminates problems associated with backing 
substrates.  
Cannot be used to test high 
stiffness materials. 
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Table 3. Cont. 
Method/ 
technique 
Description/applications Advantages Disadvantages 
In vivo 
mechanical 
testing 
Pulses of air or poking 
mechanisms are used to test 
materials. Used to measure 
corneal hysteresis by comparing 
inward and outward pressure 
values [164]. 
Can be performed on live patients. Changes in 
mechanical properties can be directly linked to 
medical conditions [165]. 
In vivo tests are difficult to 
apply to in vitro models. 
Unsuitable for prolonged 
culture periods. Sample 
contamination. Creep,  
stress-relaxation and  
stress-strain relationships 
are yet to be assessed. 
Strip 
extensiometry 
(coupon testing) 
Involves applying a tensile force 
to dissected strips with constant 
width of corneal tissue that are 
gripped and stretched via the 
application of a tensile force. Is 
used to calculate the Young’s 
modulus, yield strength and 
ultimate tensile strength of the 
cornea and equivalents. 
A relatively simple technique [151]. 
Inexpensive. Can be used to compare corneas 
of different species with each other [152,166]. 
Commonly used to determine the properties of 
engineering materials [151]. Has been 
previously used to characterize DCs [55] 
Unreliable [151]. Does not 
account for corneal 
curvature unless complex 
calculations are employed 
[162]. Stress distribution of 
corneal tissue is not 
uniform. Destructive [151]. 
Cannot be used to study 
whole tissues. Problems 
associated with sample 
gripping. Complex 
calculations involved [151]. 
Ultrasound 
A biomicroscopy technique which 
utilizes high frequency 
transducers, creating 2D images 
from backscattered ultrasonic 
waves [167].  
Used to visualize numerous 
ocular structures and to detect in 
vivo foreign bodies. 
Allows for detailed surface imaging up to 5 mm 
in depth. Allows for quantitative assessments of 
the anterior ocular surface to be made [168]. 
Non-invasive technique. Can be applied in vivo 
and in vitro. 
Expensive. Yields results 
that are too high when 
compared to known 
measurements [168]. 
5. Recellularization Techniques  
For DCs to have clinical utility as a suitable alternative graft material it is critical that they perform 
as well as or better than cadaveric donor corneas in vivo. It is therefore important that the processed 
grafts can integrate into the host tissue, and form functional corneal tissue. Restoration of function in 
DCs is likely to be highly reliant on the grafts ability to be recellularized by the relevant cell types of 
the tissue. Recellularization strategies for DCs can be divided into two areas: (i) In vivo implantation 
of the DC, allowing host cells to repopulate the graft post-surgery; or (ii) Seeding the construct ex vivo, 
for downstream transplantation of a cellularized graft.  
5.1. In Vivo Recellularization 
The clinical use of a DC, relying on host cell repopulation to create the desired functional tissue, is 
arguably the simplest and lowest risk strategy. Clinical delivery of a tissue seeded with even one cell 
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type significantly raises both the manufacturing complexity, as well as the clinical evidence threshold 
required by regulators [169].  
The majority of research into in vivo recellularization has been reported in animal models. As 
discussed earlier, much of this work has explored recellularization through investigation of the 
biocompatibility of such constructs in a xenotransplantation model, typically involving grafting 
porcine DCs into healthy and offended corneas of New Zealand white (NZW) rabbits. The surgical 
delivery of these constructs has been performed by one of two procedures: a small disc of the DC 
inserted into a small pocket within the host corneal stroma (intra-lamellar grafting) or alternatively, a 
partial thickness corneal transplant (anterior lamellar grafting). 
5.1.1. Intra-Lamellar Grafting 
The most common surgical model used to assess corneal substitutes is implantation of the substrate 
within intra-lamellal pockets in rabbit corneas [44,63,65,66]. Typically, the host corneas have not had 
prior pathologies and are not modeling disease states. A small incision is made on one side of the host 
cornea, parallel to the corneal surface, forming a stromal pocket (Figure 5Bi). A test substrate can 
easily be inserted within, before the corneal pocket is sutured closed (Figure 5Bii). Inserting a DC disc 
into the corneal stroma offers little understanding about the quality of epithelial and endothelial 
integration, although the method does demonstrate stromal cell migration. This model is most useful as 
an assessment of graft immunogenicity. Histological cross sections at the experimental endpoint can be 
used to show if undesirable mononuclear immune cells interact with the investigated matrices. 
The range of techniques used to decellularize corneas has resulted in variable rates of success of 
stromal cell infiltration. Interestingly, histological analysis of DCs produced using high hydrostatic 
pressure showed little host stromal cell infiltration even after periods of 1 year [63,66]. The same 
observations were also reported by Xu et al. (2008) [44] and Pang et al. (2010) [65], when grafting 
acellular corneas processed with Triton X-100 and SDS respectively. Despite this, these acellular 
grafts were not seen to ellicit an immune or inflammatory response in the form of an influx of  
immune competent cells. Nor were they seen to produce any undesirable responses by clinical 
examination [44,63,65,66]. 
DCs which can be naturally repopulated with corneal stromal cells, without eliciting an 
inflammatory response in vivo, have been a target for several groups [61]. Du and Wu (2011) [61] 
reported stromal cell infiltration in SDS treated grafts up to 24 weeks after grafting. However, close 
analysis of the histological cross sectioning appears to give limited evidence of stromal cell in-growth. 
The most positive results demonstrating stromal cell in-growth using this model have been reported by 
Xiao et al. [74] (2011). In this investigation, the cornea, decellularized by PLA2, was freeze dried to 
improve the porosity of the stromal matrix. Ninety days after intra-lamellal implantation, a large 
number of stromal cells were seen to have repopulated the implant.  
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Figure 5. Schematic representation of in vivo recellularization techniques. 
 
5.1.2. Anterior Lamellar Grafting 
Another popular alternative to intralamellar grafting is a partial thickness graft, also known as 
anterior lamellar grafting. This model involves prior preparation of a graft bed through removal of a  
6 mm diameter, 100 µm deep, portion of the host cornea, removing the epithelium and anterior stroma 
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(Figure 5Ci). DC matrices are then grafted to the bed with the use of nylon sutures (Figure 5Cii). This 
model is far more useful from a translational perspective than that of intra-lamellar grafting. Firstly, 
the use of partial thickness corneal grafts is becoming routine clinical practice in treating indications in 
which only the epithelium and anterior stroma is damaged [5,170]. Secondly, this method allows 
assessment of surface epithelialization of the graft materials, in addition to stromal cell in-growth [68]. 
Using anterior lamellar grafting, Wu et al. (2009) [68] were able to demonstrate excellent 
epithelialization and stromal cell infiltration in PLA2 treated corneas. It was reported that bi-layered 
epithelialization of the graft was achieved within 10 days of implantation with further stratification 
occurring over time. Li et al. (2011) [71] reported more recently, complete re-epithelialization of feline 
grafts decellularized with PLA2 over 4 days, although the surgical delivery in this report was more 
attuned to a full thickness corneal transplant. Other groups have also described a full epithelial 
monolayer formed over the DCs within a 4 to 10 day timeframe [64,69]. Wu et al. (2009) [68] noted 
an increase in transparency of DCs over time, attributed to the developing epithelium, which was able 
to regulate the stromal hydration. On implantation, the PLA2 treated DCs swelled considerably, with 
notable changes to the collagen fibril diameter and arrangement. However, post-epithelialization of the 
graft, the native character of the stromal fibrils was restored through the gradual reduction in water 
content, in turn leading to improved transparency [171]. The same report also acknowledged 
significant levels of migration of ―activated‖ or fibroblastic stromal cells from the host stroma into the 
implant. The numbers of these cells within the grafts were seen to change over time, with cells in the 
graft after 80 days reported as quiescent, a phenotype akin to keratocytes. However, it is important to 
note that these phenotypes were characterized by morphology alone, in TEM experiments.  
There have been reports of DCs delivered by anterior lamellar grafting causing adverse reactions. 
The grafting of porcine corneas decellularized through a hypotonic treatment was seen to recruit huge 
numbers of cells into the matrix [69]. Whilst the authors gave no evidence as to whether these were 
indeed CD4 or CD8 positive immune competent cells, it was acknowledged that cell number and 
position within the graft would normally be indicative of an immune response. Despite this, the 
authors claim to have seen no evidence of rejection through clinical examination. 
5.1.3. Limbal Stroma Reconstruction 
There is only one example of the in vivo use of DCs in limbal reconstruction. Herein, Huang et al. 
(2011) [73] assessed several different constructs as scaffolds suitable for limbal stroma reconstruction. 
This in vivo model involved the excision of a small portion of sclero-corneal lamellae creating a limbal 
defect (Figure 5Di). An anterior lamellar graft of one of four constructs was then used to assess 
suitability in limbal reconstruction. The study used PLA2
 
to decellularize a portion of limbal stroma, 
and investigate how well this scaffold could restore a limbal defect. The decellularized limbal stroma 
afforded the best results of the four substrates tested, showing the least infiltration by immune 
competent cells. In addition, the decellularized limbal stroma cultivated the most desirable cellular 
phenotype of epithelial cells, repopulating the acellular graft. This paper was an important addition to 
previous work that had demonstrated the utility of PLA2 treated corneal grafts [68,74]. 
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5.2. Ex Vivo Recellularization and Cell Sources 
An alternative assessment of recellularization of DCs is seeding individual cell types upon or within 
the acellular matrix ex vivo. These cellular constructs are then typically cultivated in tissue culture 
conditions relevant to the cell source under investigation. Ex vivo recellularization experiments have 
been used to either assess the biocompatibility of the matrix, or to develop a cellularized graft, which 
would be suitable for transplantation [6,65]. As would be expected there have been reports of the use 
of epithelial, stromal and endothelial cells. Sources of disagreement between protocols in this area 
appear to be variations in cell source, seeding density, cell delivery method, and culture conditions.  
5.2.1. Epithelial Cells 
In vivo, there are several layers to the corneal epithelium and cells are constantly being renewed via 
a balanced process of proliferation, differentiation and cell death. The original source of these 
epithelial cells is the limbal epithelial crypts, a stem cell niche found in the outer ring of the  
cornea [172,173]. As the epithelium is self-renewing, as long as the limbus of the cornea is intact, an 
ideal replacement matrix would allow for re-epithelialization by the host’s own cells. If a limbal stem 
cell deficiency is present or the limbus is missing, a limbal stem cell transplant can be performed [174]. 
It is possible to culture human corneal epithelial cells in vitro, either by explant or single cell  
cultures [175–179], and it is conceivable that cultured epithelial cells could be used to repopulate the 
epithelial layer of a DC, but there would need to be an intact basement membrane to support the cells. 
There is also the possibility of using stem cells, such as induced pluripotent stem cells (iPSC) [180,181], 
embryonic stem cells (ESCs) [182–184] or adult stem cells to generate corneal epithelial cells for 
implants [185–187]. 
Multiple groups have investigated the seeding of epithelial cells on the surface of DCs. The 
standard seeding method is to pipette extracted primary limbal epithelial cells, usually of rabbit or 
human origin, onto the denuded basement membrane [44,65,67,69,72,79] (Figure 6A). An area of 
contention is the optimal seeding density for these cells. Seeding densities have been reported as  
5 × 10
3
 cells/mm
2 
[44,79]; 1 × 10
4
 cell/mm
2
 [69]; and ~1.5 × 10
4
 cell/mm
2 
[72]. Despite these 
differences in seeding density, all groups have demonstrated a stable stratified or bilayered epithelium 
across the surface of the DCs [44,69,72,79]. 
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Figure 6. Schematic representation of ex vivo recellularization techniques. 
 
 
5.2.2. Corneal Stromal Cells 
The stroma of the cornea contains a population of cells conventionally known as keratocytes [188,189]. 
In vivo, keratocytes sparsely populate the stroma, remaining quiescent and exhibiting a dendritic 
morphology, with extensive cellular contacts [190–193]. The function of these cells is to maintain 
structure and transparency of the stroma by producing and maintaining ECM proteins, such as collagen 
and proteoglycans [58,190,194–200]. Markers traditionally used to identify keratocytes include 
aldehyde dehydrogenase (ALDH), keratocan, transketolase, CD133 and CD34 [191,201–205] 
Recellularization of the stroma is arguably the most challenging, from a TE perspective. This is 
because the cells are required to be in an even dispersion in a dense 3D matrix. In addition, keratocytes 
in the native healthy corneal stroma are quiescent and thus do not proliferate [206]. For recellularizing 
the corneal stroma, groups have predominantly used primary stromal cells either directly following 
extraction from the cornea [76] or extracted and expanded before seeding [6]. These cell types have 
then been delivered to the DC in an attempt to repopulate the stroma. 
Keratocytes can be isolated from the corneal stroma using collagenase treatment and subsequently 
cultured in vitro. However, once transferred to tissue culture plastic, the keratocyte phenotype rapidly 
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disappears and alternative cell populations emerge, dependent on the culture environment [207–209]. 
When grown in high serum-containing medium, such as Dulbecco’s modified Eagle’s medium 
(DMEM) with 10% fetal bovine serum (FBS), the extracted stromal cells take on a fibroblastic 
phenotype, and are said to be ―activated‖ [207,210–214]. In vivo, this ―activation‖ is associated with 
response to injury, as the keratocytes begin to exhibit morphological characteristics of fibroblasts and 
commence tissue remodeling [207,215]. In severe injuries or later stages of remodeling, a 
myofibroblast phenotype also appears, that actively secretes ECM components, such as α-smooth 
muscle actin (α-SMA). This can cause scar formation and loss of corneal transparency [190,216,217]. 
This transition in vitro is useful when modeling corneal injury, but for the purposes of recellularizing 
DCs, this is no longer the native keratocyte phenotype that is required. Previously, it was thought that 
once keratocytes became fibroblastic, it was an irreversible state, but more recently there is evidence 
that in vitro restoration of the native niche environment and careful tailoring of culture conditions has 
the potential to revert cultured (activated, fibroblastic) stromal cells back to a healthy, native 
keratocyte phenotype [218–220]. A 3D-environment may be an important factor in instigating this 
reversal, thus recellularization of DCs with activated stromal fibroblasts, could cause cells to revert to 
their quiescent keratocyte phenotype. 
Evidence has been presented demonstrating that the corneal stroma contains progenitor mesenchymal 
stem cells (MSCs) that play a role in corneal regeneration. These cells exhibit properties of MSCs, 
expressing MSC-associated cell surface markers such as CD29, CD73 CD90 and CD105, and possess 
the ability to differentiate down the osteogenic, chondrogenic and adipogenic lineages [191,221,222]. 
Recently, our group has discovered several sub-populations of different phenotypes within corneal 
stromal cells, including MSCs and the characteristic keratocyte, which possess the CD34
+
 phenotype. 
We have shown that these CD34
+
 cells have the ability to differentiate into corneal epithelial cells 
(data submitted for publication) and it may be possible that these stem cells play a role in corneal 
regeneration in vivo. Therefore, corneal stem cells may have the potential to be exploited for 
recellularization of DCs.  
Many groups have seeded stromal cells on the anterior surface of DCs (Figure 6B), expecting 
gravity and cell migration to afford a good distribution of cells in the stroma [6,44,62,76]. The 
principal limitation with this seeding method is inadequate cell infiltration. The stromal cells form 
confluent layers on the anterior surface and show little sign of in-growth [44,76]. 
Alternative approaches to improve the distribution of stromal cells in the matrix have also been 
reported using an intra-stromal injection into the lamellae with needles of small bore size  
(Figure 6C) [65,69,72,74]. Typically, five to ten injections are made at different positions into the 
corneal stroma. Seeding densities reported for intra stromal injections have been reported as  
5 × 10
4 
cells/stroma [74]; 5 × 10
5
 cells/stroma [65]; up to ~ 1.4 × 10
6 
cells/stroma [72]. Shafiq et al. 
(2012) [72] delivered the largest number of stromal cells and arguably demonstrated the most 
convincing restoration of the native stromal cell distribution. DAPI stained cross-sections showed 
excellent distribution of cells within the DC following 5 weeks culture. In addition, this report offers 
evidence that the stromal cells may be returning to their quiescent phenotype, using immunohistochemistry 
to stain for ALDH. 
Attempts to improve the porosity of DCs were reported by Xiao et al. (2011) [74] in which a  
post-decellularization freeze drying process was used to disrupt the lamellae. In this investigation 
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freeze dried constructs were seeded at a density of 2.5 × 10
5
 stromal cells/stroma using an  
intra-stromal injection, achieving a good distribution of stromal cells following 12 days of culture. 
Disappointingly, there was no non-freeze dried control in this experiment to reference, but histological 
evidence showed a clear difference to typical DC stroma. 
5.2.3. Endothelial Cells 
Corneal endothelial cells have very limited proliferative capacity in vivo, dividing rarely in the adult 
cornea [223,224], thus wounding and trauma of the endothelium cannot be reversed. If there is a 
severe loss of corneal endothelial cells and the ability to pump water away from the cornea is lost, the 
only effective therapy is to replace the entire endothelium, usually with one from a cadaveric donor. A 
therapy which supports an intact endothelial layer, would be a major achievement and this could be 
performed using a DC.  
Human corneal endothelial cells can be isolated and cultivated in vitro, but long-term culture is 
difficult to achieve, with the exception of embryonic or very young donors [225–228]. In vivo, corneal 
endothelial cells are tightly adhered to the Descemet’s membrane and detaching cells from this 
substratum can be damaging due to prolonged enzyme exposure. Once detached, the cells need to be 
cultured on a refined substrate comprising key components of the basement membrane such as 
collagen type IV, laminin, fibronectin and chondroitin sulfate [229,230]. More recent developments 
have improved the prospects for endothelial cell culture with specialist medium that allows for 
improved cell survival [231–234]. This medium requires the presence of GFs such as fibroblast growth 
factor (FGF), epidermal growth factor (EGF) and nerve growth factor (NGF). 
There is evidence suggesting the existence of corneal endothelial stem cells, present in the 
periphery of human cornea [235–237], that show promise as a cell source for corneal endothelial 
regeneration. Other sources of stem cells that show potential for corneal endothelial differentiation 
include MSCs [238], bone-marrow derived endothelial progenitors [239], neural crest cells [240] and 
corneal stromal stem cells [241]. If stem cells could be effectively differentiated into large numbers of 
corneal endothelial cells, these could subsequently be utilized to create a functioning endothelium on a 
substrate such as a DC. 
Currently, relatively little work has been performed investigating the recellularization of the 
posterior surface of DCs with endothelial cells, predominantly due to difficulties associated with 
extracting and expanding primary endothelial cells [44,69,232]. Proulx et al. (2009) [232] have used 
freeze thaw cycles to devitalize human corneas, which were then seeded with primary expanded feline 
endothelial cells, of unknown passage, upon the Descemet’s membrane. After 24 hours of tissue 
culture, a complete endothelial monolayer had been achieved. The endothelial monolayer showed the 
expected morphology and expressed the function-related proteins ZO-1, Na
+
/K
+
-ATPase, and the  
Na
+
/HCO3
−
 co-transporter.  
5.3. In Vivo versus ex Vivo Recellularization 
To date, groups have investigated recellularization of DCs through both in vivo implantation and 
subsequent recellularization; and ex vivo via primary cell extraction and expansion, before seeding 
onto the DC and implanting into the host. In vivo recellularization evidence is confined to 
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epithelialization and stromal cell in-growth, as no published work has investigated the in vivo  
re-endothelialization of such scaffolds. In general, in vivo epithelialization occurs in most cases, rapidly 
and without complication. Epithelialization over grafts has also been reported in other constructs in 
both animal models and humans and is not foreseen to be a significant problem, that requires ex vivo 
handling [242]. The largest question appears to be whether or not stromal recellularization should be 
carried out in vivo or ex vivo. Implantation of a completely acellular construct naturally has advantages 
in its manufacturing simplicity and reduced immunogenicity, however in vivo, there have been few 
convincing examples to date of significant stromal cell repopulation. Those that have shown success 
have had to modify the matrix to increase porosity, disrupting the matrix, and even then significant 
infiltration is only seen over extended time periods [74]. Ex vivo seeding of stromal cells through  
intra-stromal injection has shown some encouraging results, and may offer a means to control the 
distribution and differentiation of the culture sensitive stromal cells. However, this approach is likely 
to be far more burdensome when it comes to clinical translation. The predominant issue with ex vivo 
seeding of cells is the possibility of inducing an immune response from the host due to the allogeneic 
cell source. However, the risk of this is equal to the risk of performing a normal allogeneic cadaveric 
donor graft. 
6. Alternative Use of Human Decellularized Tissues for Toxicity Testing 
Another potential avenue for the use of human DCs that have been cell seeded ex vivo is the 
production of a more relevant human cornea substitute for use in toxicity testing and the development 
of new ocular drugs, as a robust non-animal alternative. The complexity and uniqueness of the cornea 
often makes the development of ocular drugs particularly challenging. The cornea is sensitive to 
various irritants and many substances can cause serious irreversible damage to the cornea, including 
ocular drugs. Before potential new ophthalmic drugs can be used routinely, they have to undergo many 
rigorous toxicity and permeation tests. Pharmaceuticals, cosmetics, toiletries, household, industry, 
agricultural, and military products are all potential irritants to the eye [243]. In order to ensure that 
they are safe for their intended use, all manufactured consumer products and ingredients must be tested 
and eye irritation potential assessed. Eye toxicity tests are therefore required to provide information 
that ensures that products are safely manufactured and labeled. Currently, no reliable human corneal 
substitutes exist for drug and toxicity testing. 
The current international standard assay for acute ocular toxicity is the rabbit in vivo Draize eye  
test [244]. The procedure involves the application of 0.1 mL (100 mg solid) test substance onto the eye 
of a conscious rabbit for 4 hours. The rabbits are observed for up to 14 days for signs of irritation 
including redness, swelling, discharge, cloudiness, blindness etc. [243]. The observed degree of 
irritancy allows chemicals to be classified, ranging from non/mildly irritant to strongly irritant. Draize 
testing is often criticized due to lack of repeatability and over-prediction of human responses [244], 
primarily due to interspecies differences. In addition, the test is often disapproved of by animal activist 
groups, due to animal stress. Moreover, research councils, government and independent organizations 
are working extensively on the replacement, refinement and reduction (the 3Rs) of animal use in 
research and testing [245]. Furthermore, EU directives and guidelines (Directive 2010/63/EU) [246] 
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―strongly encourage‖ in vitro screening of all components prior to animal testing and encourage the 
use of alternative testing when possible or available. 
As an alternative to in vivo testing, enucleated eye tests using isolated rabbit eyes were first 
introduced in 1981 by Burton et al. [247]. They are ethically advantageous with reduced costs. Corneal 
thickness, opacity and fluorescein retention [248] are tested to reveal adverse reactions to test substances. 
Eye irritation is primarily determined by the extent of initial injury, which correlates with the extent of 
cell death and ultimately the outcome of an irritant on an eye [244]. Generally, slight irritants damage the 
superficial epithelium, mild irritants penetrate further to damage the stroma and severe irritants penetrate 
through the cornea and damage the endothelium [244]. However, as with Draize testing, interspecies 
differences lead to discrepancies in irritation compared to human responses.  
Slaughterhouse waste has been investigated as an alternative tissue source [248]. Porcine corneas are 
often used for corneal testing [249], although chicken enucleated eye tests (CEET) are widely accepted 
to be the most reliable and accurate slaughterhouse tissue for assessing the eye irritation potential of test 
materials [248]. CEET are often used as a pre-screen for Draize testing. Although, despite promising 
outcomes, the in vivo Draize testing results still overrule ex vivo results if discrepancies occur.  
In vitro toxicity testing using cultured cells, often on collagen hydrogels, are advantageous 
compared to in vivo and ex vivo testing because they are relatively inexpensive, are simple and can be 
rapidly manufactured. Rabbit corneal epithelial (RCE) cells have been cultured on collagen hydrogels 
using air-liquid interface techniques. The RCE model [250] aims to mimic the native rabbit corneal 
epithelium. To validate the model, thirty chemicals with known degrees of eye irritation (from Draize 
testing) have been tested. Eye irritation potency can be estimated by using colorimetric MTT assays as 
a measurement of viability. However, the RCE model is somewhat limited because it only models the 
epithelial layer and cannot be used to determine the possible effects of drugs penetrating the stroma 
and endothelium. 
Although promising results have been obtained from both enucleated eye testing and RCE models, 
they share the common disadvantage of interspecies differences regarding anatomy and physiology. 
Such differences produce discrepancies in permeation studies and toxicity tests [251,252]. Pathogens 
are often species specific and this regularly causes new drugs to fail in clinical trials [253]. In 
response, human cell based culture models are becoming more established, but the principal hurdle is 
the successful manufacture of an in vitro cornea with comparable barrier functions to the native 
cornea. Thus, there is still a growing need for credible, human-derived in vitro models [253]. 
Griffith et al. (1999) [36] produced the first functional equivalent of a human cornea using 
immortalized human corneal cells. A collagen-chondrotin sulfate substrate cross-linked with 
glutaraldehyde was used as a tissue matrix. Initially, a thin layer of endothelial cells were grown in a 
culture dish. Keratocytes and support proteins were added, before finally adding the final epithelial 
layer. Gross morphology, transparency and histology were reported to be similar to that of a natural 
cornea. Tests performed using mild detergents determined that the constructed cornea had a similar 
gene expression and wound-healing response when compared to human eye-bank corneas.  
In the wake of this work, Reichl et al. (2001) [254] claimed to have successfully manufactured a 
human corneal equivalent for in vitro drug permeation studies by culturing all three corneal cell types 
in a collagen hydrogel matrix. Three reagents commonly used in ophthalmic drugs to treat glaucoma 
and inflammatory diseases were tested and permeation data obtained was compared with those from 
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excised porcine cornea and a porcine cornea construct [251,252]. The human cornea construct had 
similar epithelial barrier properties to a native cornea with only small ultrastructural differences, 
possibly due to lack of tears and blinking. For all reagents examined, there was increased permeability 
in the TE constructs compared to the exercised porcine cornea, although the differences were relatively 
small. Unfortunately, there was no data available for comparison with an excised human cornea, as in 
the studies by Griffith et al. (1999) [36].  
The MatTek Corporation has developed a commercially available 3D corneal epithelial model 
based upon human derived epidermal keratinocytes from human foreskin [28,255], marketed as 
EpiOcular
TM
. Although it is been used by numerous cosmetic companies in place of Draize testing, as 
of yet EpiOcular
TM
 has not been formally validated [255] as it is unable to predict responses of 
chemicals that affect the lower layers of the cornea, or that are dependent upon epithelial-stromal 
cellular interactions [28].  
Despite numerous screening tests, currently there is no validated in vitro ocular irritation test to 
replace the heavily criticized use of animals. This is partly due to a lack of understanding of the 
underlying mechanisms of eye irritation [250], a possible the lack of innervation [23] and an apparent 
reluctance of regulatory bodies to accept new in vitro corneal constructs. However, recent European 
directives have prohibited the use of laboratory animals in toxicity testing, particularly the use of the 
Draize eye irritancy test [37], thus the need for alternative testing is crucial, particularly in the 
development of new ophthalmic drugs. Human DCs that have been regenerated using specific, defined 
cell lines have the potential to be the primary method of toxicity testing for many of the requirements 
discussed above. They would offer a full-thickness, functional tissue that is ethically advantageous and 
species specific, capable of accurately predicting human responses of a whole spectrum of irritants, 
ranging from mildly to severely irritant, in a reliable, reproducible manner. 
7. Conclusions 
The limited availability of suitable corneal donor tissue has led to the development of alternative 
corneal equivalents including KPros and TE corneas. It has been impossible thus far to replicate the 
structural complexity of the native cornea in vitro and artificial equivalents only simulate physical 
characteristics, topography and lack intrinsic functionality [3]. Human DCs theoretically provide an 
authentic scaffold for corneal tissue reconstruction that can maintain structural complexity and provide 
authentic cell-cell and cell-matrix interactions, which are pivotal for cell differentiation and conservation 
of specialized functions. 
There is currently no standard technique for decellularization of the cornea and a range of protocols 
have been attempted with varying levels of success. The important factor in any decellularization 
protocol is achievement of a balance of maximum cell debris removal with minimal structural 
disruption. This requires more investigation with the ultimate aim of producing a standardized and 
repeatable decellularization protocol. There are many options for both destructive and non-destructive 
characterization of a DC, with non-destructive techniques showing potential as part of manufacturing 
processes. The possibility of incorporating cells within the human DCs has been considered, but there 
is as of yet no evidence to show the necessity of this process. 
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Ultimately, although many challenges are ahead, human DCs may provide a promising alternative 
to donor corneas in addition to becoming an alternative method of toxicity testing and allowing the 
study of corneal biology and potential new drug development. 
8. Perspectives 
Although bioscaffold design has significantly advanced in recent years, we are yet to achieve a 
suitable corneal equivalent that is capable of mimicking the complex lamellar structure of the native 
tissue. Simply put, the most suitable matrix for tissue engineered corneas is the corneal tissue itself.  
The most attractive strategy at current for development of a clinical product would be the 
production of a DC seeded with stromal cells. Through intra-stromal injection, one could ensure 
suitable distribution of stromal cells within the matrix, and in an ideal situation, control stromal cell 
phenotype through conditioning with specific medium.  
At the time of this review there were three registered clinical trials involving DCs. Two of the three 
reported investigation of decellularized grafts from human source, and the other from porcine  
origin [256]. The clinical data from the solitary completed study has now been published, in a peer 
reviewed journal, with promising results [170]. This further validates the vast potential of DCs, 
demonstrating the vital need for further research and exploitation.  
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